| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | |
|---|---|---|---|
| Revenue | |||
| Cost of revenue | |||
| Operating income | |||
| Operating margin | |||
| Net income | |||
| Net profit margin | |||
| Cash on hand | |||
| Change in cash | |||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 33.50 mm | 33.50 mm | 33.50 mm | 33.50 mm | 33.50 mm | 33.50 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 4.67 mm | 5.58 mm | 4.00 mm | 5.09 mm |
| Cash used (since last report) | n/a | n/a | 23.66 mm | 28.28 mm | 20.27 mm | 25.77 mm |
| Cash remaining | n/a | n/a | 9.84 mm | 5.22 mm | 13.23 mm | 7.74 mm |
| Runway (months of cash) | n/a | n/a | 2.1 | 0.9 | 3.3 | 1.5 |
| 13F holders | Current |
|---|---|
| Total holders | 22 |
| Opened positions | 7 |
| Closed positions | 35 |
| Increased positions | 4 |
| Reduced positions | 3 |
| 13F shares | Current |
|---|---|
| Total value | 9.00 bn |
| Total shares | 24.32 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| BML Investment Partners | 5.75 mm | $0.00 |
| BML Capital Management | 5.75 mm | $6.15 bn |
| Adjuvant Global Health Technology Fund | 2.60 mm | $0.00 |
| Ra Capital Management | 2.00 mm | $2.06 mm |
| Biotechnology Value Fund L P | 1.56 mm | $0.00 |
| TCG Crossover GP I | 1.56 mm | $1.70 mm |
| PFE Pfizer | 1.36 mm | $0.00 |
| Brii Biosciences | 1.05 mm | $0.00 |
| Vanguard | 1.04 mm | $1.11 bn |
| Acuitas Investments | 445.78 k | $476.99 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 26 Feb 25 | Stephen David Prior | Common Stock | Grant | Acquire A | No | No | 0 | 28,000 | 0.00 | 61,313 |
| 26 Feb 25 | Stephen David Prior | Stock Option Common Stock | Grant | Acquire A | No | No | 1.13 | 56,000 | 63.28 k | 56,000 |
| 26 Feb 25 | Joshua M Eizen | Common Stock | Grant | Acquire A | No | No | 0 | 58,500 | 0.00 | 175,172 |
| 26 Feb 25 | Joshua M Eizen | Stock Option Common Stock | Grant | Acquire A | No | No | 1.13 | 117,000 | 132.21 k | 117,000 |
| 26 Feb 25 | Eric Easom | Common Stock | Grant | Acquire A | No | No | 0 | 145,250 | 0.00 | 246,380 |
| 26 Feb 25 | Eric Easom | Stock Option Common Stock | Grant | Acquire A | No | No | 1.13 | 290,500 | 328.26 k | 290,500 |
| 26 Feb 25 | Lucy Day | Common Stock | Grant | Acquire A | No | No | 0 | 46,500 | 0.00 | 79,170 |
| 26 Feb 25 | Lucy Day | Stock Option Common Stock | Grant | Dispose A | No | No | 1.13 | 93,000 | 105.09 k | 93,000 |
| 26 Feb 25 | Sanjay Chanda | Common Stock | Grant | Acquire A | No | No | 0 | 50,250 | 0.00 | 80,074 |
| 26 Feb 25 | Sanjay Chanda | Stock Option Common Stock | Grant | Acquire A | No | No | 1.13 | 100,500 | 113.56 k | 100,500 |
